Oct-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Is this your brand?
See your full sales and distribution data: where you sell, how you're priced, and how you rank against the brands next to you on the shelf.
See your brand's dataCarry this brand in your store?
Headset Retailer is free. Connect your POS and see what's selling and what's sitting.
Sign up freeWhere to Buy
Rise (MI) is stocked at 264 licensed dispensaries across Michigan, with the deepest coverage in Detroit, New Buffalo, Lansing, Monroe, and Ann Arbor. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Rise (MI) shifted its category mix in October 2026 toward Capsules, which jumped to 33.79% share with 79.34% year-over-year growth and 44.57% month-over-month, while Concentrates held the lead at 36.21% share with a -13.86% YoY decline but a 1.30% MoM uptick. At the same time, Topical contracted to 19.01% share with -55.66% YoY and -31.25% MoM, and Tincture & Sublingual fell to 11.00% share with -55.90% YoY and -29.14% MoM. With brand-wide sales down -22.46% YoY but average price down -6.90% YoY to $14.55, the mix is rotating from shrinking wellness formats toward a fast-expanding ingestible segment, implying near-term volume is being backfilled by Capsules as traditional adjunct categories retrench.
The pattern implies a repositioning opportunity: leveraging Capsules’ 44.57% MoM momentum to stabilize overall decline while using Concentrates’ 1.30% MoM growth to defend the leading share position at 36.21%. Given Topical and Tincture & Sublingual’s combined 30.00% share now tied to steep YoY drops of -55.66% and -55.90%, respectively, reallocating assortment and pricing toward Capsules’ 79.34% YoY trajectory and selective Concentrates SKUs could raise conversion without broad discounting beyond the -6.90% YoY average price move. The thesis is that October 2026 marks a pivot from wellness-heavy baskets to ingestion-forward formats, suggesting merchandising and inventory should prioritize Capsules to capture incremental trips while maintaining core identity via Concentrates.
Competitive Landscape
Rise (MI) sits at rank #53 in MI Concentrates for October 2026, down 7 positions year over year from #46, and 1 position lower than July 2026’s #52, while still far off its peak at #21 in December 2024; meanwhile, Rkive Cannabis climbed from #3 to #1 with 102.5% YoY sales growth and Uniq Pressure surged from #20 to #3 on 441.5% YoY growth, as Cannalicious Labs slid from #2 to #5 alongside a 35.1% YoY sales decline; the mix of upward mobility among challengers and declines among incumbents implies Rise (MI)’s downward rank trajectory risks entrenchment in the lower half unless it taps segments where rapid-share shifts are occurring.
Notable Products
Rise (MI) leans on a concentrated core in October 2026, with the top 10 items generating 39.5% of sales and the leading CBG Tablets 20-Pack (200mg CBG) alone at 7.2%. With 0% of sales from new launches in the last six months, the lineup depends on established products, so most of its sales ride on a relatively small set of repeat sellers.
Peer avg: average price of the same product type and package size in the same states that month.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.






